Quest Diagnostics to Add Roche's Elecsys to Alzheimer's Biomarker Test Portfolio

MT Newswires Live

Yesterday

Quest Diagnostics (DGX) said Monday it is adding Roche's Elecsys Phospho-Tau Plasma blood test to its AD-Detect portfolio of biomarker tests to detect Alzheimer's disease.

The company said it plans to offer a laboratory test service based on Elecsys in Q4 and incorporate the Roche test into future AD-Detect panels in 2027.

Quest said the US Food and Drug Administration has cleared Roche's Elecsys blood test to assess amyloid pathology associated with Alzheimer's disease across primary and specialty care settings.

Quest also said it will launch its newest AD-Detect lab-developed blood test with low 10% indeterminate rate so more patients can receive an actionable insight.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www-web.itiger.com/news/2661276223"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2661276223\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2661276223?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-24 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661276223","market":"sh","top_or_hot":-1,"title":"Quest Diagnostics to Add Roche's Elecsys to Alzheimer's Biomarker Test Portfolio","media":"MT Newswires Live","content":"<html><body><p> Quest Diagnostics (DGX) said Monday it is adding Roche's Elecsys Phospho-Tau Plasma blood test to its AD-Detect portfolio of biomarker tests to detect Alzheimer's disease.</p><p>The company said it plans to offer a laboratory test service based on Elecsys in Q4 and incorporate the Roche test into future AD-Detect panels in 2027.</p><p>Quest said the US Food and Drug Administration has cleared Roche's Elecsys blood test to assess amyloid pathology associated with Alzheimer's disease across primary and specialty care settings.</p><p>Quest also said it will launch its newest AD-Detect lab-developed blood test with low 10% indeterminate rate so more patients can receive an actionable insight.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Quest Diagnostics to Add Roche's Elecsys to Alzheimer's Biomarker Test Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nQuest Diagnostics to Add Roche's Elecsys to Alzheimer's Biomarker Test Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-24 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Quest Diagnostics (DGX) said Monday it is adding Roche's Elecsys Phospho-Tau Plasma blood test to its AD-Detect portfolio of biomarker tests to detect Alzheimer's disease.</p><p>The company said it plans to offer a laboratory test service based on Elecsys in Q4 and incorporate the Roche test into future AD-Detect panels in 2027.</p><p>Quest said the US Food and Drug Administration has cleared Roche's Elecsys blood test to assess amyloid pathology associated with Alzheimer's disease across primary and specialty care settings.</p><p>Quest also said it will launch its newest AD-Detect lab-developed blood test with low 10% indeterminate rate so more patients can receive an actionable insight.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2506951958.HKD","symbol_name":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2661276223","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2661276223","pubTimestamp":1787574276,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Quest Diagnostics  said Monday it is adding Roche's Elecsys Phospho-Tau Plasma blood test to its AD-Detect portfolio of biomarker tests to detect Alzheimer's disease.The company said it plans to offer a laboratory test service based on Elecsys in Q4 and incorporate the Roche test into future AD-Detect panels in 2027.Quest said the US Food and Drug Administration has cleared Roche's Elecsys blood test to assess amyloid pathology associated with Alzheimer's disease across primary and specialty care settings.Quest also said it will launch its newest AD-Detect lab-developed blood test with low 10% indeterminate rate so more patients can receive an actionable insight.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2506951958.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) INC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","LU1854103824.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) INC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","BK4567":"ESG概念","BK4196":"保健护理服务","BK4583":"猴痘概念","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","BK4588":"碎股","DGX":"奎斯特诊疗","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC"},"translate_title":"Quest Diagnostics 将罗氏 Elecsys 添加到阿尔茨海默氏症生物标志物测试产品组合中","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DGX":1.5},"content_text":"Quest Diagnostics (DGX) said Monday it is adding Roche's Elecsys Phospho-Tau Plasma blood test to its AD-Detect portfolio of biomarker tests to detect Alzheimer's disease.The company said it plans to offer a laboratory test service based on Elecsys in Q4 and incorporate the Roche test into future AD-Detect panels in 2027.Quest said the US Food and Drug Administration has cleared Roche's Elecsys blood test to assess amyloid pathology associated with Alzheimer's disease across primary and specialty care settings.Quest also said it will launch its newest AD-Detect lab-developed blood test with low 10% indeterminate rate so more patients can receive an actionable insight.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}